Fluzoparib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Fluzoparib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 24 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Fluzoparib can convert its Small molecule drug profile and PARP biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Fluzoparib (query alias: Fluzoparib) |
|---|---|
| Modality / target | Small molecule drug; PARP; PARP inhibitors |
| Highest global status | Approved |
| Originator | Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
| Active developers | Jiangsu Hengrui Pharmaceuticals Co., Ltd., Luzsana Biotechnology, Inc. |
The MCP disease footprint includes Germline BRCA-mutated, HER2-negative metastatic breast cancer, Fallopian Tube Carcinoma, Ovarian Epithelial Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07647653 | Phase 2 | Not yet recruiting | 120 | 12-month Progression-Free Survival (PFS) Rate |
| ChiCTR2600123414 | Phase 2 | Not yet recruiting | 45 | (CA-125 response) |
| NCT07382713 | Phase 2 | Not yet recruiting | 43 | Progression-Free Survival (PFS) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
SHR-1701 combined with fuzuloparib and chemotherapy as first-line therapy for advanced lung squamous cell carcinoma: Efficacy and safety results from a phase II study.
Phase 2; n=71; evaluation: Positive. Reported fields: DCR = 98.6 %
Fuzuloparib combined with abiraterone acetate and prednisone (AA-P) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Interim results from the FUZUPRO trial.
Phase 3; n=496; evaluation: Positive. Reported fields: rPFS = 22.8 month ; rPFS = 13.9 month ; rPFS = 21.2 month
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
Phase 3; n=203; evaluation: Positive. Reported fields: mPFS(per BICR) = 6.7 month (95%CI, 4.2 - 7.6); mPFS(per BICR) = 11.0 month (95%CI, 8.4 - 13.1); mPFS(per BICR) = 3.0 month (95%CI, 1.6 - 5.3)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Fluzoparib addresses Germline BRCA-mutated, HER2-negative metastatic breast cancer, Fallopian Tube Carcinoma, Ovarian Epithelial Carcinoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 45 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: PARP records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-03-05 | Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal | Phase 1 | US$169.7M upfront; US$1,235.5M milestones; US$1,500.6M stated total |
| 2025-09-08 | Idience Co. Licenses Anti-cancer Drug Candidate in Russia, Middle East | Phase 1/2 | US$50.0M stated total |
| 2025-08-12 | Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies | Preclinical | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “一种PARP抑制剂的制备方法”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 24 July 2026. Counts and status fields may change as source records update.
